These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15197994)

  • 1. [Amyloidosis].
    Homma N
    Nihon Rinsho; 2004 May; 62 Suppl 5():607-11. PubMed ID: 15197994
    [No Abstract]   [Full Text] [Related]  

  • 2. [Renal disease in multiple myeloma].
    Hiromura K; Nojima Y
    Nihon Rinsho; 2007 Dec; 65(12):2229-34. PubMed ID: 18069265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis and treatment in systemic amyloidosis].
    Ikeda S
    Rinsho Byori; 2008 Feb; 56(2):121-9. PubMed ID: 18404826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Lachmann HJ; Wechalekar AD; Gillmore JD
    N Engl J Med; 2008 Jan; 358(1):91-2; author reply 92-3. PubMed ID: 18175386
    [No Abstract]   [Full Text] [Related]  

  • 6. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP;
    N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Secondary amyloidosis associated with rheumatoid arthritis (RA)].
    Koseki Y; Goto M
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():278-82. PubMed ID: 15799361
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Comenzo RL; Steingart RM; Cohen AD
    N Engl J Med; 2008 Jan; 358(1):92; author reply 92-3. PubMed ID: 18175384
    [No Abstract]   [Full Text] [Related]  

  • 9. [Can amyloidosis regress?].
    Dray JM; Blétry O
    Rev Prat; 1997 Oct; 47(16):1798-801. PubMed ID: 9453206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal amyloidosis: pathogenesis and therapy.
    Jones NF
    Clin Nephrol; 1976 Nov; 6(5):459-64. PubMed ID: 136327
    [No Abstract]   [Full Text] [Related]  

  • 13. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Autologous peripheral blood hematopoietic cell transplantation in the treatment of AL-amyloidosis].
    Smirnova AG; Smirnov AV; Zander A; Afanas'ev BV
    Ter Arkh; 2010; 82(10):61-4. PubMed ID: 21341467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose therapy and autologous transplantation in amyloidosis-AL.
    Majolino I; Marcenò R; Pecoraro G; Scimé R; Vasta S; Liberti G; Rizzo A; Indovina A; Caronia F
    Haematologica; 1993; 78(1):68-71. PubMed ID: 8098314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Secondary amyloidosis in patients with rheumatoid arthritis(RA)].
    Inada S
    Nihon Rinsho; 2002 Dec; 60(12):2417-22. PubMed ID: 12510371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloidosis: a changing clinical perspective.
    Jacobs P; Ruff P; Wood L; Moodley D; Mansvelt E
    Hematology; 2007 Apr; 12(2):163-7. PubMed ID: 17454199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].
    Arbustini E; Gavazzi A; Merlini G
    Ital Heart J Suppl; 2002 Jun; 3(6):590-7. PubMed ID: 12116807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrotoxic potential of Bence Jones proteins.
    Solomon A; Weiss DT; Kattine AA
    N Engl J Med; 1991 Jun; 324(26):1845-51. PubMed ID: 1904132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy options in systemic AL-amyloidosis with renal involvement].
    Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.